The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor

被引:310
作者
Basu, S
Nagy, JA
Pal, S
Vasile, E
Eckelhoefer, IA
Bliss, VS
Manseau, EJ
Dasgupta, PS
Dvorak, HF
Mukhopadhyay, D
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/87895
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Angiogenesis has an essential role in many important pathological and physiological settings. It has been shown that vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), a potent cytokine expressed by most malignant tumors, has critical roles in vasculogenesis and both physiological and pathological angiogenesis. We report here that at non-toxic levels, the neurotransmitter dopamine strongly and selectively inhibited the vascular permeabilizing and angiogenic activities of VPF/VEGF. Dopamine acted through D2 dopamine receptors to induce endocytosis of VEGF receptor 2, which is critical for promoting angiogenesis, thereby preventing VPF/VEGF binding, receptor phosphorylation and subsequent signaling steps. The action of dopamine was specific for VPF/VEGF and did not affect other mediators of microvascular permeability or endothelial-cell proliferation or migration. These results reveal a new link between the nervous system and angiogenesis and indicate that dopamine and other D2 receptors, already in clinical use for other purposes, might have value in anti-angiogenesis therapy.
引用
收藏
页码:569 / 574
页数:6
相关论文
共 41 条
[1]   Blood vessels in liver metastases from both sarcoma and carcinoma lack perivascular innervation and smooth muscle cells [J].
Ashraf, S ;
Loizidou, M ;
Crowe, R ;
Turmaine, M ;
Taylor, I ;
Burnstock, G .
CLINICAL & EXPERIMENTAL METASTASIS, 1997, 15 (05) :484-498
[2]   DOPAMINERGIC RECEPTORS LINKED TO ADENYLATE-CYCLASE IN HUMAN CEREBROMICROVASCULAR ENDOTHELIUM [J].
BACIC, F ;
UEMATSU, S ;
MCCARRON, RM ;
SPATZ, M .
JOURNAL OF NEUROCHEMISTRY, 1991, 57 (05) :1774-1780
[3]   Dopamine, a neurotransmitter, influences the immune system [J].
Basu, S ;
Dasgupta, PS .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 102 (02) :113-124
[4]   Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue [J].
Basu, S ;
Dasgupta, PS .
DIGESTIVE DISEASES AND SCIENCES, 1999, 44 (05) :916-921
[5]   Role of dopamine in malignant tumor growth [J].
Basu, S ;
Dasgupta, PS .
ENDOCRINE, 2000, 12 (03) :237-241
[6]   EXPRESSION OF THE VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR GENE IN CENTRAL-NERVOUS-SYSTEM NEOPLASMS [J].
BERKMAN, RA ;
MERRILL, MJ ;
REINHOLD, WC ;
MONACCI, WT ;
SAXENA, A ;
CLARK, WC ;
ROBERTSON, JT ;
ALI, IU ;
OLDFIELD, EH .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :153-159
[7]   Evolution of the management of acute myocardial infarction: a 20th century saga [J].
Braunwald, E .
LANCET, 1998, 352 (9142) :1771-1774
[8]  
Brown LF, 1997, REGULATION ANGIOGENE
[9]   Progressive loss of perivascular nerves adjacent to colorectal cancer [J].
Chamary, VL ;
Robson, T ;
Loizidou, M ;
Boulos, PB ;
Burnstock, G .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2000, 26 (06) :588-593
[10]   ANTITUMOR EFFECT OF IP DOPAMINE IN MICE BEARING EHRLICH ASCITES-CARCINOMA [J].
DASGUPTA, PS ;
LAHIRI, T .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1987, 113 (04) :363-368